Secondary hyperparathyroidism (SHPT), a common and serious complication of end-stage renal disease (ESRD), is characterized by increased parathyroid hormone (PTH), calcium and phosphate levels, with substantial mortality [1, 2]. This evidence concerns the gene PTH and chronic kidney disease.